Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

Aliment Pharmacol Ther. 2004 Feb 15;19(4):407-14. doi: 10.1046/j.1365-2036.2004.01818.x.

Abstract

Background: Predicting factors for the outcome of conventional Helicobacter pylori triple therapy have been identified. Of these, the presence of the CagA gene is a strong predictor of successful treatment. Our preliminary data show that this factor becomes irrelevant when sequential therapy is used.

Aim: To identify predicting factors for the outcome of H. pylori eradication using two therapeutic schemes (triple and sequential) of equal duration (10 days).

Methods: Ninety-six patients with H. pylori infection were randomly assigned to receive one of the following therapeutic schemes: group A: rabeprazole (20 mg b.d.) plus amoxicillin (1 g b.d.) for 5 days, followed by rabeprazole (20 mg b.d.) plus tinidazole (500 mg b.d.) and clarithromycin (500 mg b.d.) for a further 5 days; group B: rabeprazole (20 mg b.d.) plus amoxicillin (1 g b.d.) and clarithromycin (500 mg b.d.) for 10 days. Age, sex, smoking, endoscopic and histological findings, and CagA and VacA status were considered as candidates for a model of multivariate analysis which used therapeutic outcome as the dependent variable. CagA and VacA status were assessed by polymerase chain reaction on DNA isolated from gastric antral specimens.

Results: The sequential scheme was significantly more effective than prolonged triple therapy (P < 0.05). Smoking (P < 0.001) and the absence of the CagA gene (P < 0.05) were significantly associated with the failure of triple therapy, but the effectiveness of sequential treatment was not predicted by these factors.

Conclusion: Our data suggest that sequential therapy is not affected by bacterial and host factors which have, until now, predicted the outcome of conventional eradication treatments.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Amoxicillin / administration & dosage
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Ulcer Agents / administration & dosage*
  • Antigens, Bacterial / genetics
  • Bacterial Proteins / genetics
  • Benzimidazoles / administration & dosage
  • Clarithromycin / administration & dosage
  • DNA / analysis
  • Drug Evaluation
  • Drug Therapy, Combination
  • Dyspepsia / drug therapy*
  • Dyspepsia / genetics
  • Dyspepsia / microbiology
  • Female
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / genetics
  • Helicobacter pylori / genetics*
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / analogs & derivatives
  • Peptic Ulcer / drug therapy*
  • Peptic Ulcer / genetics
  • Peptic Ulcer / microbiology
  • Polymerase Chain Reaction / methods
  • Rabeprazole
  • Risk Factors
  • Smoking
  • Tinidazole / administration & dosage
  • Treatment Outcome

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Antigens, Bacterial
  • Bacterial Proteins
  • Benzimidazoles
  • VacA protein, Helicobacter pylori
  • cagA protein, Helicobacter pylori
  • Tinidazole
  • Rabeprazole
  • Amoxicillin
  • DNA
  • Clarithromycin
  • Omeprazole